MedDataX Logo

Epstein Barr Virus Infection in Patients With Radiologically Isolated Syndrome

NCT ID: NCT05815108

Last Updated: 2025-05-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

156 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-03-15

Study Completion Date

2023-03-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The clinical course of RRMS patients is variable. Among RIS-Consortium international cohorts, one third of RIS patients progressed to MS at 5 years and 52.2% at 10 years. Biomarkers predictive of MS conversion are key elements to organize personalized medical care, for both follow-up and treatment strategies. EBV seems to be an interesting candidate regarding its involvement MS pathophysiology. It can be easily assess in blood sample in contrast to others prognostic biomarkers validated in RIS : oligoclonal bands and NfL levels in cerebrospinal fluid and serum. In RIS, treatment targeting EBV could significantly modify the course of the disease. The investigators aim to make the fisrt description of the EBV epidemiology (immunoglobulin (Ig)M and IgG anti-viral capsid antigen (VCA), IgG anti Epstein-Barr nuclear antigen (EBNA)) among RIS patients and to investigate a correlation between the different antibodies' titers (IgM VCA, IgG VCA, IgG EBNA) and the course of the disease (clinical conversion or evidence of disease activity (EDA)).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Environmental Risk Factors in Multiple Sclerosis Development: Epidemiological Study of EBV Infection and Vitamin D Deficiency in RIS Patients

NCT07256431

Radiologically Isolated Syndrome Epstein-Barr Virus Infections
COMPLETED

RIS International Cohort

NCT05388331

Multiple Sclerosis Radiologically Isolated Syndrome
RECRUITING

Comparison of Digital Biomarkers in Subjects With Radiologically Isolated Syndrome (RIS) and Multiple Sclerosis (MS) Patients With Clinically Normal Neurological Examination

NCT07135752

Radiologically Isolated Syndromes; Multiple Sclerosis
RECRUITING NA

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants

NCT01485003

Relapsing-Remitting Multiple Sclerosis
COMPLETED

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

NCT01185717

Multiple Sclerosis
COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis Radiologically Isolated Syndrome Epstein-Barr Virus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

RIS Patient

RIS patients validated by the RIS expert group

NO INTERVENTION

Intervention Type OTHER

NO INTERVENTION

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NO INTERVENTION

NO INTERVENTION

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients with RIS confirmed by the RIS expert center of the Nice CHU; EBNA status at RIS diagnosis available

Exclusion Criteria

none
Minimum Eligible Age

15 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier Universitaire de Nice

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Nice University Hospital

Nice, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

23Neuro01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Trial to Assess the Safety and Feasibility of Adoptive Cell Therapy with Autologous EBV-specific Cytotoxic T Lymphocytes (CTL) in Patients with a First Clinical Episode Highly Suggestive of Multiple Sclerosis
NCT02912897 RECRUITING PHASE1
JC Virus Reactivation in Multiple Sclerosis
NCT02004444 COMPLETED
Stratification of Risks of Conversion of Radiologically Isolated Syndromes (RIS) by Identifying Biomarkers in Serum and Cerebrospinal Fluid.
NCT06395662 ACTIVE_NOT_RECRUITING
Evaluation of Early Changes Visible to the Diffusion MRI in Response to Two Years of Treatment With Tysabri in Patients With Multiple Sclerosis
NCT02904876 TERMINATED PHASE4
Bacille Calmette-Guérin (BCG) Vaccine In Radiologically Isolated Syndrome (RIS)
NCT03888924 RECRUITING PHASE2
Magnetic Resonance Imaging (MRI) Follow-up of Macrophagic Infiltration in MS Patients Treated With Tysabri
NCT00752778 TERMINATED PHASE4
A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
NCT05532163 TERMINATED PHASE4
Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)
NCT01080027 COMPLETED
Famciclovir in Multiple Sclerosis
NCT05283551 UNKNOWN PHASE2
Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study
NCT00937677 COMPLETED
COVID-19 on Disease Activity in Radiologically Isolated Syndrome Cohort
NCT05387395 COMPLETED
Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
NCT01440101 COMPLETED PHASE2/PHASE3
Mechanisms of Disease Severity in Multiple Sclerosis: an Integrative Multimodal Study
NCT03369106 ACTIVE_NOT_RECRUITING
A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED)
NCT00239655 TERMINATED PHASE2
B Cell Differentiation in MS
NCT03744351 COMPLETED NA
Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis
NCT01416155 COMPLETED PHASE2
A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration
NCT03689972 COMPLETED PHASE3
RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.
NCT05758831 RECRUITING PHASE3
JC-Virus (JCV) Antibody Program
NCT01070823 COMPLETED
Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)
NCT00001248 RECRUITING
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
NCT01070836 COMPLETED
Predicting Disease Activity and Rebound Risk in MS Patients Treated With Sphingosine-1-phosphate Receptor Modulators (S1PRM)
NCT05828901 RECRUITING
National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Phase of Multiple Sclerosis
NCT02937285 COMPLETED PHASE3
Real World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort
NCT04580381 COMPLETED
Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis
NCT01767701 COMPLETED PHASE2